成人(含孕妇)戒烟干预:美国预防服务工作组更新证据报告与系统综述
结果显示药物和行为干预可提高非孕妇戒烟率,行为干预对孕妇有效,但电子烟和孕妇药物治疗证据有限。
要点
- 药物联合行为干预、NRT、安非他酮、伐尼克兰及临床建议均提高非孕妇戒烟率。
- 行为干预可提高孕妇晚期戒烟率,但NRT对孕妇戒烟无显著效果。
- 电子烟戒烟效果证据不一致,安全性数据有限。
核心结论
- 强证据表明多种药物和行为干预单独或联合可有效提高非孕妇成人戒烟率。
- 孕妇行为干预有效,但药物治疗戒烟数据有限。
- 电子烟戒烟有效性和安全性证据有限且结果不一致。
研究设计与样本
- 检索PubMed、PsycInfo等数据库至2020年9月25日,采用随机效应荟萃分析。
主要发现
- 药物联合行为干预RR 1.83(95%CI 1.68-1.98),NRT RR 1.55(95%CI 1.49-1.61)。
- 安非他酮RR 1.64(95%CI 1.52-1.77),伐尼克兰RR 2.24(95%CI 2.06-2.43)。
- 临床建议RR 1.76(95%CI 1.58-1.96),均对比最小支持或安慰剂。
- 孕妇行为干预晚期戒烟RR 1.35(95%CI 1.23-1.48)。
- 孕妇NRT对比安慰剂RR 1.11(95%CI 0.79-1.56,n=2033),无显著差异。
关键数值与推荐
- 药物联合行为干预、NRT、安非他酮、伐尼克兰及行为建议均与6个月以上戒烟率升高相关。
- 无药物与严重不良事件相关。
- 电子烟对6-12个月戒烟效果研究结果不一致,无严重不良事件增加。
临床怎么用
- 非孕妇成人可选用药物联合行为干预提高戒烟成功率。
- 孕妇优先推荐行为干预戒烟。
- 电子烟戒烟需谨慎,证据不充分。
局限性
- 孕妇药物治疗戒烟数据有限。
- 电子烟戒烟有效性和安全性证据有限且不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: It has been estimated that in 2018 nearly 20% of adults in the US were currently using a tobacco product. OBJECTIVE: To systematically review the effectiveness and safety of pharmacotherapy, behavioral interventions, and electronic cigarettes for tobacco cessation among adults, including pregnant persons, to inform the US Preventive Services Task Force. DATA SOURCES: PubMed, PsycInfo, Database of Abstracts of Reviews of Effects, Cochrane Database of Systematic Reviews, Centre for Reviews and Dissemination of Health Technology Assessment; surveillance through September 25, 2020. STUDY SELECTION: Systematic reviews of tobacco cessation interventions and randomized clinical trials that evaluated the effects of electronic cigarettes (e-cigarettes) or pharmacotherapy among pregnant persons. DATA EXTRACTION AND SYNTHESIS: Independent critical appraisal and data abstraction; qualitative synthesis and random-effects meta-analyses. MAIN OUTCOMES AND MEASURES: Health outcomes, tobacco cessation at 6 months or more, and adverse events. RESULTS: Sixty-seven reviews addressing pharmacotherapy and behavioral interventions were included as well as 9 trials (N = 3942) addressing e-cigarettes for smoking cessation and 7 trials (N = 2285) of nicotine replacement therapy (NRT) use in pregnancy. Combined pharmacotherapy and behavioral interventions (pooled risk ratio [RR], 1.83 [95% CI, 1.68-1.98]), NRT (RR, 1.55 [95% CI, 1.49-1.61]), bupropion (RR, 1.64 [95% CI, 1.52-1.77]), varenicline (RR, 2.24 [95% CI, 2.06-2.43]), and behavioral interventions such as advice from clinicians (RR, 1.76 [95% CI, 1.58-1.96]) were all associated with increased quit rates compared with minimal support or placebo at 6 months or longer. None of the drugs were associated with serious adverse events. Five trials (n = 3117) reported inconsistent findings on the effectiveness of electronic cigarettes on smoking cessation at 6 to 12 months among smokers when compared with placebo or NRT, and none suggested higher rates of serious adverse events. Among pregnant persons, behavioral interventions were associated with greater smoking cessation during late pregnancy (RR, 1.35 [95% CI, 1.23-1.48]), compared with no intervention. Rates of validated cessation among pregnant women allocated to NRT compared with placebo were not significantly different (pooled RR, 1.11 [95% CI, 0.79-1.56], n = 2033). CONCLUSIONS AND RELEVANCE: There is strong evidence that a range of pharmacologic and behavioral interventions, both individually and in combination, are effective in increasing smoking cessation in nonpregnant adults. In pregnancy, behavioral interventions are effective for smoking cessation, but data are limited on the use of pharmacotherapy for smoking cessation. Data on the effectiveness and safety of electronic cigarettes for smoking cessation among adults are also limited and results are inconsistent.
引用
- Patnode CD, Henderson JT, Coppola EL, et al. Interventions for Tobacco Cessation in Adults, Including Pregnant Persons: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021. PMID: 33464342. doi:10.1001/jama.2020.23541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。